What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

Lantheus Holdings has received FDA approval for TAUKLARIFY (florquinitau F 18 injection), also known as MK-6240, a radiodiagnostic agent used in positron emission tomography imaging of the brain.¹ The agent is indicated for adults with cognitive impairment who are being evaluated for Alzheimer's disease, and it works by identifying tau neurofibrillary tangle pathology, one of the hallmark biological changes associated with the disease. The approval does not extend to evaluating tauopathies unrelated to Alzheimer's disease, and the company has noted that safety and effectiveness outside that population have not been established.

What Did the Clinical Data Show?

The approval rests on 2 blinded read studies drawing on imaging data from more than 500 subjects across three clinical trials.¹ Participants spanned a range of cognitive states, from cognitively unimpaired individuals to those with mild cognitive impairment and mild Alzheimer's disease dementia, giving reviewers a view of how the imaging agent performs across different points in disease progression. Each subject received an intravenous dose of approximately 185 MBq of the agent, and scans were read by independent, blinded reviewers who classified images as positive or negative for tau pathology against a pre-established reference standard.

In the first study, covering 279 subjects, positive percent agreement across readers ranged from 80% to 88%, while negative percent agreement ranged from 98% to 99%.¹ The second study, covering 338 subjects, showed somewhat lower positive percent agreement, ranging from 68% to 82%, with negative percent agreement between 93% and 99%. Agreement between readers was described as high in both studies. Safety was assessed across 1734 subjects, with the most frequently reported reactions, each occurring in less than 1% of subjects, including headache, nausea, injection site reactions, dizziness, and abdominal discomfort.

Why Does This Approval Matter for Drug Developers?

This approval is notable for what it signals about the broader Alzheimer's disease pipeline.¹ Tau imaging has increasingly been positioned as a complement to amyloid PET scanning, giving researchers and clinicians a fuller picture of underlying disease biology. As Keith Johnson, professor of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School, said in a press release,¹ “The use of sensitive quantitative tau PET imaging is essential for increasing our understanding of potential disease impacts and moving novel treatments forward.”

That dual-biomarker approach has direct implications for how disease-modifying therapies are developed, trialed, and eventually deployed in clinical practice.¹ Diagnostic imaging agents like this one are often woven into patient selection and monitoring protocols for therapeutic candidates, meaning their approval status and performance characteristics can shape trial design well beyond the diagnostics category itself.

Mary Anne Heino, executive chairperson and CEO, Lantheus, noted in the press release,¹ "As the field continues to advance, clinicians are seeking a more complete understanding of this disease, with tau PET imaging providing information that complements amyloid PET and other diagnostic tools.”

The company has indicated it will continue supporting Alzheimer's disease therapeutic programs through its pharma solutions business while it works out a path toward broader commercial availability of the newly approved agent.¹

How Does this Approval Fit into the Broader Biomarker Timeline?

TAUKLARIFY's approval arrives against the backdrop of a 2-decade shift in how Alzheimer's disease biomarkers are developed and used.² At the start of the century, tools for identifying Alzheimer's pathology were largely confined to research settings and relied on measures like hippocampal volume and cerebrospinal fluid concentrations. The introduction of an amyloid-binding radiotracer in 2004 marked an early turning point, allowing plaque distribution to be visualized directly in living patients through PET imaging. Tracers capable of binding tau aggregates followed roughly a decade later, described in the literature in 2013 and 2014, laying the groundwork for approvals like TAUKLARIFY's.

That progression has not been limited to imaging. Advances in fluid biomarker assay technology, informed in part by amyloid and tau PET serving as reference standards, contributed to the emergence of accurate blood-based Alzheimer's tests around 2017 and 2018.² Biomarkers of this kind are now used throughout AD research and clinical trials, both to confirm that trial participants have the underlying pathology and to track how that pathology responds to treatment over time, a role imaging agent like TAUKLARIFY are positioned to continue serving as the field matures.

References

1. Lantheus announces FDA approval of TAUKLARIFY™ (florquinitau F 18) injection. GlobeNewswire. Press Release. August 14, 2026. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-fda-approval-tauklarifytm-florquinitau-f-18
2. Ibanez L. The evolving roles of imaging and fluid biomarkers for Alzheimer disease over the past quarter century. Alzheimers Dement. 2025;21(suppl 2):e101336. doi:10.1002/alz70856_101336